Barclays’s BeOne Medicines Ltd ONC Stock Holding History

Barclays’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,500	Closed	-$3.12M	–	5708
2026 Q1	$3.12M	Hold	10,500	–	–	﹤0.01%	2099
2025 Q4	$3.19M	Sell	10,500 -3,000	-22%	-$982K	﹤0.01%	2591
2025 Q3	$4.6M	Buy	+13,500	New	+$4.1M	﹤0.01%	2266
2024 Q4	–	Sell	-57,000	Closed	-$12.8M	–	5536
2024 Q3	$12.8M	Buy	57,000 +27,000	+90%	+$4.86M	﹤0.01%	1312
2024 Q2	$4.28M	Buy	+30,000	New	+$4.62M	﹤0.01%	1636
2024 Q1	–	Sell	-15,000	Closed	-$2.71M	–	5425
2023 Q4	$2.71M	Buy	+15,000	New	+$2.71M	﹤0.01%	2664
2018 Q4	–	Sell	-8,600	Closed	-$1.48M	–	7410
2018 Q3	$1.48M	Buy	+8,600	New	+$1.45M	﹤0.01%	3240

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's ONC Position: Q2 2026 in Review

Barclays increased its BeOne Medicines Ltd (ONC) stake by 9.9% in Q2 2026, buying an estimated $735K and bringing the position to 27,716 shares worth $7.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1598.

Barclays first reported a position in ONC in Q4 2016 and has held it in 39 quarters since. The position peaked at $19.7M in Q4 2020. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Barclays held 27,716 shares of BeOne Medicines Ltd worth $7.9M as of Q2 2026.
Barclays bought 2,494 BeOne Medicines Ltd shares in Q2 2026, an estimated $735K.
BeOne Medicines Ltd made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1598 holding.
Barclays first reported a position in BeOne Medicines Ltd in Q4 2016 and has held it in 39 quarters since.
Barclays's BeOne Medicines Ltd position peaked at $19.7M in Q4 2020.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.